PTCT PTC Therapeutics, Inc. - Common Stock
$72,62
Preço · Ago 19, 2026
Fundamentais a partir de Jul 30, 2026
Intervalo 52 Semanas
$48–$91
57% of range
Classificação do Analista
BUY
21 analysts
Preço-Alvo
$98
+35% upside
P/E (TTM)
9.3
ROE
-331.5%
Margem de Lucro Líquido
39.4%
Sobre PTC Therapeutics, Inc. - Common Stock Visão geral da empresa da Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Ler mais
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
PTCT Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$72.62
Capitalização de Mercado
$5.92B
P/E (TTM)
9.3
EPS (TTM)
$7.78
Receita (TTM)
$1.73B
Rendimento div.
—
ROE
-331.5%
Dívida/Capital
-1.4
Intervalo 52 Semanas
$48 – $91
PTCT Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$1.73B
2016-12-31
→
2025-12-31
EPS
$7.78
2019-12-31
→
2025-12-31
Fluxo de caixa livre
$702M
2016-12-31
→
2025-12-31
Margens
39.4%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
PTCT
Mediana de Pares
P/E (TTM)
9.3
37.2
P/S (TTM)
3.4
9.9
P/B
-28.8
8.3
EV / EBITDA
4.7
—
Price / FCF (Preço / FCF)
8.4
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
PTCT
Mediana de Pares
Operating Margin (Margem Operacional)
50.1%
—
Net Profit Margin (Margem de Lucro Líquido)
39.4%
-15.1%
ROA
29.7%
-23.3%
ROE
-331.5%
-30.6%
ROIC
1044.7%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
PTCT
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
-1.4
—
Current Ratio (Índice de liquidez corrente)
2.3
6.3
Quick Ratio (Índice de Liquidez Seca)
2.2
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
PTCT
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
114.5%
—
Revenue CAGR 3Y (CAGR Receita 3A)
35.3%
—
Revenue CAGR 5Y (CAGR Receita 5A)
35.4%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
PTCT
Mediana de Pares
PTCT Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
21 analistas
- Compra forte 6 28,6%
- Compra 11 52,4%
- Manter 3 14,3%
- Venda 1 4,8%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
14 analistas · 2026-08-13
Mediana
$98.00
Agora
$72.62
Mín
$70.00
Máx
$130.00
Alvo mediano
$98.00
+34,9%
Alvo médio
$97.86
+34,8%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
1.9%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $0.92 | $0.43 | 0.49% |
| 31 de Março de 2026 | $-0.03 | $-0.48 | 0.45% |
| 31 de Dezembro de 2025 | $-1.67 | $0.04 | -1.7% |
| 30 de Setembro de 2025 | $0.20 | $-1.40 | 1.6% |
| 30 de Junho de 2025 | $-0.83 | $-1.08 | 0.25% |
| 31 de Março de 2025 | $10.04 | $-0.22 | 10.3% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | — |
| COGT | $5.72B | -16.4 | — | — | -83.1% | — |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | — |
| ERAS | $1.06B | -8.5 | — | — | -35.7% | — |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
| PBLS | — | — | — | — | — | — |
| CELC | $4.81B | -26.3 | — | — | -244.3% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Balanço Patrimonial 27
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Fluxo de Caixa 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 13
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Demonstração de Resultados 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | -155,203,905 | 78,471,119 | 78,151,240 | 78,115,836 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | -163,341,037 | 87,115,369 | 78,151,240 | 86,385,922 | -153,301,665 | 76,925,523 | 76,725,070 | 76,496,127 | -148,999,422 | 75,377,997 | 74,730,433 | 73,729,284 | -142,514,082 | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Balanço Patrimonial 27
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Fluxo de Caixa 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Avaliação (TTM) 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.02B | $1.84B | · | $1.76B | $1.74B | $1.77B | · | $790M | $807M | $841M | · | $848M | $817M | $752M | · | $670M | |
| Net Income TTM | $32M | $815M | · | $711M | $596M | $569M | · | $-430M | $-523M | $-562M | · | $-580M | $-599M | $-527M | · | $-522M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | 313.7 | 7.3 | · | 7.7 | 7.5 | 8.3 | · | -6.6 | -4.4 | -3.9 | · | -2.9 | -5.0 | -6.6 | · | -6.8 | |
| P/S | 6.6 | 3.1 | · | 2.8 | 2.2 | 2.3 | · | 3.6 | 2.9 | 2.7 | · | 2.0 | 3.8 | 4.8 | · | 5.4 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| P / FCF | · | -93.7 | · | · | · | 4.6 | · | · | · | 36.5 | · | · | · | -90.2 | · | · | |
| EV / EBITDA | 34.6 | 66.9 | · | 1161.8 | -62.2 | 2.3 | · | -39.0 | -38.4 | 163.9 | · | -16.7 | -15.7 | -51.8 | · | -52.8 | |
| EV / FCF | · | -67.1 | · | · | · | 2.6 | · | · | · | 26.6 | · | · | · | -97.4 | · | · | |
| EV / Revenue | 5.0 | 2.2 | · | 2.0 | 1.3 | 1.3 | · | 2.7 | 1.9 | 1.9 | · | 2.3 | 4.0 | 5.1 | · | 5.4 | |
| Earnings Yield | 0.32% | 13.8% | · | 13.1% | 13.4% | 12.1% | · | -15.2% | -22.6% | -25.8% | · | -34.9% | -20.2% | -15.1% | · | -14.6% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $1.73B | $807M | $938M | $699M | $539M |
| Margem Operacional % | 50.1% | -37.5% | -46.9% | — | -69.5% |
| Lucro líquido | $683M | $-363M | $-627M | $-559M | $-524M |
| EPS Diluído | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -1.4 | -0.3 | -0.3 | — | 300.0 |
| Índice de liquidez corrente | 2.3 | 2.4 | 2.0 | — | 1.9 |
| Índice de Liquidez Seca | 2.2 | 2.2 | 1.7 | — | 1.7 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $702M | $-114M | $-187M | — | $-280M |
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 404 declarantes · $5.4B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 83 (+22 vs trimestre anterior) | 43 (-9 vs trimestre anterior) | 133 (-4 vs trimestre anterior) | 109 (+6 vs trimestre anterior) | +2.1M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | $631.875.072 | 7.746.415 | 11,70% | Ações |
| JANUS HENDERSON GROUP PLC | $479.178.655 | 7.034.622 | 8,87% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401.986.014 | 4.928.111 | 7,45% | Ações |
| STATE STREET CORP | $375.136.515 | 4.598.952 | 6,95% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $305.000.589 | 3.739.127 | 5,65% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $292.435.873 | 3.585.091 | 5,42% | Ações |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159.563.645 | 1.956.156 | 2,96% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $155.132.041 | 1.901.417 | 2,87% | Ações |
| Hood River Capital Management LLC | $141.818.662 | 1.738.613 | 2,63% | Ações |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140.519.660 | 1.722.688 | 2,60% | Ações |
| TANG CAPITAL MANAGEMENT LLC | $122.355.000 | 1.500.000 | 2,27% | Ações |
| Driehaus Capital Management LLC | $117.469.528 | 1.440.107 | 2,18% | Ações |
| Jefferies Financial Group Inc. | $110.693.916 | 1.357.042 | 2,05% | Ações |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94.361.749 | 1.156.819 | 1,75% | Ações |
| Pictet Asset Management Holding SA | $93.629.635 | 1.147.844 | 1,73% | Ações |
| ARMISTICE CAPITAL, LLC | $87.393.690 | 1.071.395 | 1,62% | Ações |
| Blue Sparrow, LLC /DE | $85.705.599 | 1.050.700 | 1,59% | Ações |
| D. E. Shaw & Co., Inc. | $77.478.857 | 949.845 | 1,43% | Ações |
| Palo Alto Investors LP | $74.950.268 | 918.846 | 1,39% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.449.436 | 790.112 | 1,19% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $59.015.895 | 723.500 | 1,09% | Ações |
| Boston Partners | $57.080.953 | 699.871 | 1,06% | Ações |
| FMR LLC | $56.956.987 | 698.259 | 1,05% | Ações |
| BANK OF AMERICA CORP /DE/ | $56.350.840 | 690.828 | 1,04% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53.377.940 | 654.382 | 0,99% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $51.486.821 | 631.199 | 0,95% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $47.953.943 | 587.887 | 0,89% | Ações |
| Ensign Peak Advisors, Inc | $41.442.128 | 508.056 | 0,77% | Ações |
| AMERICAN CENTURY COMPANIES INC | $40.866.277 | 500.995 | 0,76% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36.050.432 | 441.957 | 0,67% | Ações |
| Parkman Healthcare Partners LLC | $35.539.315 | 435.691 | 0,66% | Ações |
| LOOMIS SAYLES & CO L P | $35.387.921 | 433.835 | 0,66% | Ações |
| Defilade Capital Management, L.P. | $35.376.827 | 433.699 | 0,66% | Ações |
| GOLDMAN SACHS GROUP INC | $34.153.522 | 418.702 | 0,63% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.274.149 | 395.662 | 0,60% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $30.892.190 | 378.720 | 0,57% | Ações |
| Qube Research & Technologies Ltd | $25.398.777 | 311.374 | 0,47% | Ações |
| ARMISTICE CAPITAL, LLC | $24.471.000 | 300.000 | 0,45% | Opção de compra |
| Public Sector Pension Investment Board | $23.249.326 | 285.023 | 0,43% | Ações |
| SEGALL BRYANT & HAMILL, LLC | $22.165.424 | 271.735 | 0,41% | Ações |
| CITADEL ADVISORS LLC | $20.338.011 | 249.332 | 0,38% | Ações |
| MORGAN STANLEY | $18.990.210 | 232.808 | 0,35% | Ações |
| Boxer Capital Management, LLC | $16.314.000 | 200.000 | 0,30% | Ações |
| RHUMBLINE ADVISERS | $15.718.994 | 192.706 | 0,29% | Ações |
| AMERIPRISE FINANCIAL INC | $13.904.178 | 170.457 | 0,26% | Ações |
| PRUDENTIAL FINANCIAL INC | $13.746.176 | 168.520 | 0,25% | Ações |
| BlackRock, Inc. | $13.589.562 | 166.600 | 0,25% | Ações |
| Rock Springs Capital Management LP | $13.238.648 | 162.298 | 0,25% | Ações |
| Hudson Bay Capital Management LP | $13.033.091 | 159.778 | 0,24% | Ações |
| Russell Investments Group, Ltd. | $12.687.724 | 155.544 | 0,23% | Ações |
| Schonfeld Strategic Advisors LLC | $12.025.457 | 147.425 | 0,22% | Ações |
| MARSHALL WACE, LLP | $11.724.301 | 143.733 | 0,22% | Ações |
| Swiss National Bank | $11.539.300 | 141.465 | 0,21% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $11.063.583 | 135.633 | 0,20% | Ações |
| Legal & General Group Plc | $10.362.979 | 127.044 | 0,19% | Ações |
| CITIGROUP INC | $9.272.143 | 113.671 | 0,17% | Ações |
| FIRST TRUST ADVISORS LP | $9.246.285 | 113.354 | 0,17% | Ações |
| Longaeva Partners L.P. | $9.119.771 | 111.803 | 0,17% | Ações |
| JUPITER ASSET MANAGEMENT LTD | $8.927.184 | 109.442 | 0,17% | Ações |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $8.215.404 | 100.716 | 0,15% | Ações |
| SECTOR GAMMA AS | $8.157.000 | 100.000 | 0,15% | Ações |
| WCM INVESTMENT MANAGEMENT, LLC | $7.651.184 | 93.799 | 0,14% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $7.256.141 | 88.956 | 0,13% | Ações |
| VOYA INVESTMENT MANAGEMENT LLC | $7.239.501 | 88.752 | 0,13% | Ações |
| ALLIANCEBERNSTEIN L.P. | $7.217.488 | 105.937 | 0,13% | Ações |
| Aquatic Capital Management LLC | $6.808.648 | 83.470 | 0,13% | Ações |
| XTX Topco Ltd | $6.682.459 | 81.923 | 0,12% | Ações |
| MOORE CAPITAL MANAGEMENT, LP | $6.165.713 | 75.588 | 0,11% | Ações |
| PINNACLE ASSOCIATES LTD | $5.745.383 | 70.435 | 0,11% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $5.744.722 | 84.320 | 0,11% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $5.614.300 | 68.828 | 0,10% | Ações |
| Capricorn Fund Managers Ltd | $5.212.323 | 63.900 | 0,10% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.000.241 | 61.300 | 0,09% | Opção de compra |
| INTECH INVESTMENT MANAGEMENT LLC | $4.696.882 | 57.581 | 0,09% | Ações |
| ExodusPoint Capital Management, LP | $4.672.166 | 57.278 | 0,09% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $4.561.884 | 55.926 | 0,08% | Ações |
| BARCLAYS PLC | $4.169.858 | 51.120 | 0,08% | Ações |
| ORBIMED ADVISORS LLC | $4.005.087 | 49.100 | 0,07% | Ações |
| MetLife Investment Management, LLC | $3.932.653 | 48.212 | 0,07% | Ações |
| Point72 Europe (London) LLP | $3.829.919 | 62.407 | 0,07% | Ações |
| MILLENNIUM MANAGEMENT LLC | $3.792.516 | 46.494 | 0,07% | Ações |
| Phocas Financial Corp. | $3.766.087 | 46.170 | 0,07% | Ações |
| MARTINGALE ASSET MANAGEMENT L P | $3.627.826 | 44.475 | 0,07% | Ações |
| Quadrature Capital Ltd | $3.589.488 | 44.005 | 0,07% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.531.981 | 43.300 | 0,07% | Opção de venda |
| STATE OF WISCONSIN INVESTMENT BOARD | $3.436.299 | 42.127 | 0,06% | Ações |
| CREDIT AGRICOLE S A | $3.344.370 | 41.000 | 0,06% | Ações |
| Fisher Asset Management, LLC | $3.322.345 | 40.730 | 0,06% | Ações |
| HSBC HOLDINGS PLC | $3.200.425 | 38.732 | 0,06% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $3.134.490 | 38.427 | 0,06% | Ações |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $3.114.179 | 38.178 | 0,06% | Ações |
| CenterBook Partners LP | $3.082.938 | 37.795 | 0,06% | Ações |
| Rafferty Asset Management, LLC | $3.069.805 | 37.634 | 0,06% | Ações |
| FIFTH THIRD BANCORP | $3.044.843 | 37.328 | 0,06% | Ações |
| BURNEY CO/ | $3.044.192 | 37.320 | 0,06% | Ações |
| Vanguard Global Advisers, LLC | $3.033.180 | 37.185 | 0,06% | Ações |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | $3.007.731 | 36.873 | 0,06% | Ações |
| Louisiana State Employees Retirement System | $2.969.148 | 36.400 | 0,05% | Ações |
| JANE STREET GROUP, LLC | $2.854.950 | 35.000 | 0,05% | Opção de venda |
| CASTLEARK MANAGEMENT LLC | $2.765.223 | 33.900 | 0,05% | Ações |
Executivos da empresa 33 insiders · 13 diretores · 14 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Stuart Walter Peltz | Chief Executive Officer | 1 de Fevereiro de 2022 S | 38.728 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 de Julho de 2026 S | 83.986 | 0 | 1 | $-280.743 |
| Emily Luisa Hill | Chief Financial Officer | 1 de Fevereiro de 2022 S | 37.169 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9 de Maio de 2017 M | 37.850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 de Janeiro de 2015 M | 39.247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 de Fevereiro de 2020 M | 6.744 | 0 | 0 | $0 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9 de Julho de 2026 M | 60.299 | 0 | 20 | $-9.184.852 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 6 de Julho de 2026 M | 105.272 | 0 | 12 | $-1.254.986 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 de Junho de 2026 M | 70.199 | 0 | 1 | $-1.487.474 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 de Junho de 2026 S | 73.411 | 0 | 28 | $-7.477.160 |
| Mark Rothera | Chief Commercial Officer | 24 de Maio de 2017 M | 33.739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3 de Janeiro de 2017 A | 6.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4 de Janeiro de 2016 A | 3.239 | 0 | 0 | $0 |
| Hege Elisabeth Sollie-Zetlmayer | Conselheiro | 28 de Julho de 2026 A | 52.526 | 0 | 0 | $0 |
| Mary L. Smith | Conselheiro | 9 de Julho de 2026 M | 21.813 | 0 | 2 | $-1.425.060 |
| Stephanie Okey | Conselheiro | 7 de Janeiro de 2022 A | 4.163 | 0 | 0 | $0 |
| Emma Reeve | Conselheiro | 7 de Janeiro de 2022 A | 7.528 | 0 | 0 | $0 |
| Allan Steven Jacobson | Conselheiro | 7 de Janeiro de 2022 A | 8.348 | 0 | 0 | $0 |
| Dawn Svoronos | Conselheiro | 7 de Janeiro de 2022 A | 29.755 | 0 | 0 | $0 |
| Jerome B Zeldis | Conselheiro | 7 de Janeiro de 2022 A | 6.500 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Conselheiro | 3 de Janeiro de 2017 A | — | 0 | 0 | $0 |
| Adam Koppel | Conselheiro | 3 de Janeiro de 2017 A | 2.333.333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Conselheiro | 3 de Janeiro de 2017 A | — | 0 | 0 | $0 |
| Richard Aldrich | Conselheiro | 8 de Junho de 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Conselheiro | 16 de Março de 2015 S | 2.242 | 0 | 0 | $0 |
| Axel Bolte | Conselheiro | 25 de Junho de 2013 P | 20.000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Detentor de 10% | 17 de Dezembro de 2013 S | 2.441.504 | 0 | 0 | $0 |
| Matthew B. Klein | — | 4 de Agosto de 2026 S | 383.868 | 0 | 1 | $-705.722 |
| Michael Schmertzler | — | 2 de Janeiro de 2026 A | 163.266 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | — | 2 de Janeiro de 2026 A | 22.500 | 0 | 1 | $-916.200 |
| David P Southwell | — | 2 de Janeiro de 2026 A | 20.850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | — | 28 de Abril de 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | — | 25 de Junho de 2013 C | 2.256.882 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 3 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 declarações | 30 de Janeiro de 2015 | — | Declaração inicial | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 declarações | 12 de Novembro de 2014 | — | Declaração inicial | — | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5 de Julho de 2013 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 87 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,81% | 4.145 SH | 8 de Agosto de 2026 | Diário |
| PSCH · Invesco Exchange-Traded Fund Trust … | 3,08% | 71.992 SH | 8 de Agosto de 2026 | Diário |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 128.216 SH | 8 de Agosto de 2026 | Diário |
| XSMO · Invesco Exchange-Traded Fund Trust | 1,52% | 642.023 SH | 8 de Agosto de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,37% | 12.510 NS | 30 de Abril de 2026 | N-PORT |
| SIXS · EXCHANGE TRADED CONCEPTS TRUST | 1,30% | 22.380 NS | 31 de Maio de 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,25% | 23.662 SH | 8 de Agosto de 2026 | Diário |
| GURU · Global X Funds | 1,03% | 9.268 NS | 30 de Abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 73.928 NS | 30 de Abril de 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,83% | 10.625 NS | 30 de Abril de 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98.733 SH | 8 de Agosto de 2026 | Diário |
| VMAX · Lattice Strategies Trust | 0,72% | 5.120 NS | 30 de Abril de 2026 | N-PORT |
| IJT · iShares Trust | 0,66% | 770.376 SH | 8 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 40.257 NS | 30 de Abril de 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,49% | 3.490 NS | 31 de Maio de 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,49% | 40.488 NS | 31 de Maio de 2026 | N-PORT |
| IBB · iShares Trust | 0,44% | 588.017 SH | 8 de Agosto de 2026 | Diário |
| HQGO · Lattice Strategies Trust | 0,43% | 3.203 NS | 30 de Abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,41% | 4.514 SH | 8 de Agosto de 2026 | Diário |
| OASC · Unified Series Trust | 0,40% | 4.569 NS | 31 de Maio de 2026 | N-PORT |
| BRNY · EA Series Trust | 0,40% | 34.057 NS | 30 de Abril de 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290.018 SH | 8 de Agosto de 2026 | Diário |
| XJR · iShares Trust | 0,37% | 9.802 SH | 8 de Agosto de 2026 | Diário |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,34% | 35.034 NS | 31 de Maio de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75.795 SH | 8 de Agosto de 2026 | Diário |
| ESSC · Strategy Shares | 0,34% | 1.335 NS | 30 de Abril de 2026 | N-PORT |
| IJR · iShares Trust | 0,32% | 5.058.562 SH | 8 de Agosto de 2026 | Diário |
| IWO · iShares Trust | 0,31% | 641.280 SH | 8 de Agosto de 2026 | Diário |
| BIB · ProShares Trust | 0,31% | 3.062 NS | 31 de Maio de 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,31% | 11.451 NS | 31 de Maio de 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,30% | 39.411 NS | 31 de Maio de 2026 | N-PORT |
| SAA · ProShares Trust | 0,26% | 961 NS | 31 de Maio de 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 22.443 NS | 30 de Abril de 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 27.276 NS | 30 de Abril de 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,23% | 2.877 NS | 30 de Abril de 2026 | N-PORT |
| AFSM · First Trust Exchange-Traded Fund VI… | 0,23% | 3.003 NS | 31 de Maio de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477.030 SH | 8 de Agosto de 2026 | Diário |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,20% | 39.967 NS | 30 de Abril de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1.099.640 SH | 8 de Agosto de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,18% | 72.691 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,18% | 2.102.256 SH | 8 de Agosto de 2026 | Diário |
| LRGF · iShares Trust | 0,16% | 84.151 SH | 8 de Agosto de 2026 | Diário |
| ISCG · iShares Trust | 0,16% | 22.792 SH | 8 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,16% | 34.125 NS | 30 de Abril de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11.071 NS | 30 de Abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,15% | 3.710 NS | 31 de Maio de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35.428 SH | 8 de Agosto de 2026 | Diário |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 49.932 NS | 30 de Abril de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,14% | 5.350 SH | 8 de Agosto de 2026 | Diário |
| SMDX · Tidal Trust III | 0,13% | 2.579 NS | 30 de Abril de 2026 | N-PORT |